Member Info for Mambamentality

Another important part in the puzzle would be obtaining this patent. The description and uses of the drug are incredible: "The patent sets out the specific antioxidant, anti-inflammatory, immune-modulating, anti-viral, and anti-cancer properties of CimetrATM, designed for multiple therapeutic applications including the treatment of chronic inflammation, severe acute respiratory syndrome coronavirus (SARS-Covid, COVID-19) and heavy variants of influenza, as well as various types of cancer. This is in addition to its efficacy in relation to the regulation of the human body's circadian rhythm and homeostasis which promotes an immune response to bacterial, viral, fungal and parasitic infections. It's wide range of uses as a treatment highlights its versatility as an IMP".

Thus, if phase 3 clinical trials are successful I can imagine the company being profitable only with the sell of CimetrATM which would allow it to invest further in the other cannabinoid products they have in the pipeline.

Certainly the second half of this year is going to be very interesting here. The Canadian application also could be granted in the near future. Further orders would also be a good boost for the share price. The company is progressing well and I will hold this at least until the results of phase 3 CimetrATM.

Definitely a good time to buy back or top up. With the price of Gold above $1800 there is no reason for the SP not to recover as the actual drilling results continue to support the idea given by the historical drilling. Furthermore, the CSA noting that all previous drilling was of a high standard, and that with some minor modifications would be amenable to be included in a resource estimate in future when that is warranted further confirms that what attracted Newmont and Agnico Eagle to the ANZA project was the right information and that has only being enhanced by the current drilling.

What we know so far is that ArtemiCTM Rescue is well positioned to take advantage of a gap in the market. Treatments for Covid 19. Covid is here to stay. Looking at Chile it is clear that even after vaccinating large amounts of the population, COVID is here to stay. Thus, a treatment for COVID is desirable in any event.

The potential further uses in relation to diseases related to cytokine storm such as autoimmune diseases, inflammatory GI diseases, 'flu and chemotherapy patients means the potential is huge.

With a market cap of £83m which is the same as Kanabo group and generating cash, I think this is the best cannabis stock.

I think that our CEO is pretty driven and we receive regular updates and clearly he follows the money as ArtemiC is not even a cannabis derivative. Happy to Hold

This just adds to previous research and will give further confidence to potential customers in places which are been affected by COVID and the vaccine is not a solution such as India and Brasil.

It will also be relevant to treat any variant of Covid as all of them have in common the cytokine storm: "Preclinical and Clinical results to date have demonstrated ArtemiCTM's mechanism of action as an anti-inflammatory and immunomodulatory agent effective in the prevention of increased cytokine production, found in different variants and mutations of COVID-19; the forerunner of cytokine storm - believed to be the main reason for mortality in severe COVID-19 patients".

Interesting to see that successful ArtemiCTM Phase II clinical trials performed in India demonstrated the capacity of ArtemiCTM to improve and expedite the clinical recovery in mild to moderate patients suffering from COVID-19. I wonder whether the product is being distributed in India at this point. Surely, results should have been reported in the media there.

Very positive RNS, I will be topping up this morning.

Pokerchips. It does. The second page.
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02372074-6A1032018?access_token=83ff96335c2d45a094df02a206a39ff4

Looking at the halt in trading on 5 August 2020 named "STUDY CONFIRMS EFFECTIVENESS OF ARTEMIC ON HUMAN IMMUNE CELL", this resulted in an increase in share price from 0.022 to 0.031 the next day at the maximum point.

My take is that the news could relate to "These results now open potential market opportunities for ArtemiCTM to a wide range of
diseases related to cytokine storm such as autoimmune diseases, inflammatory GI diseases, 'flu and chemotherapy patients".

There is an element of gamble at the moment and it could go either way. However, the fact that ArtemiCTM has already completed stage two trials showing:
ArtemiCTM results deliver a full safety and efficacy profile, demonstrating to improve andexpedite the clinical recovery in moderate COVID-19 patients
? Full Trial results are supported by in vitro and in vivo studies, demonstrating the mechanism ofaction and safety profile of ArtemiCTM

Gives me some security and Makes me think that it is more likely to be good news than bad news. However, DYOR

I mean 0.23p and 0.56p of course

From a technical analysis point of view this still got plenty to go. RSI is just 71 and there are no more resistance until 23p. If that is broken, we could see 56p.

I invested here when the share price retraced to 1.30p on the back of an article from master investor. Looking at the figures provided it is clear that the company has realised a much larger loss that they were expecting and it seems they are not going to be as profitable this year as they expected either.

The figure given were:
"Until further news is known or declared I put the shares out on a target price of just 3p,
"For the year to end-December 2020 he estimates that sales revenues were up from €1.7m to €2.4m, generating a smaller pre-tax loss of €2.3m against €3.7m previously.
That might look scary to you – however, the following might attract you to the company and its potential.

For the current year Arden is going for sales to leap over 20 times to €48.1m, then next year almost doubling to €80.6m, producing pre-tax profits of €7.4m then €13.8m respec-tively.
Now that really is an impressive leap forward and why I rate the shares of this penny stock as being capable of rising significantly".

https://masterinvestor.co.uk/equities/eqtec-for-lovers-of-penny-shares-this-really-is-a-sustainable-proposition/

Resistance broken next resistance is at 0.58,70p which is the 200 day moving average.

Evil Knievil: A new Angle. Interesting article. Although, he gets wrong the concept of a biopsy, I guess he gets correct the potential of the treatment as a biopsy is in any event an invasive procedure. Following a tip from him Amigo share price did very well so that could be replicated here.

https://masterinvestor.co.uk/evil-diaries/evil-knievil-a-new-angle/

I guess a lot of people including me are waiting to receive the next set of results before investing back. I believe that if the results are mainly gold then the share price could recover. No idea how the market will react if we see more zinc that gold but based on the reaction after the last set of results does not look positive.

Hole MAP-077 located an additional 90m down dip of MAP-075, had been completed back in February this year and visually demonstrated similar intersections of massive sulphide and pervasive silicification. Thus, whether it replicates hole 075 as to be of a different mineralogical domain, transitioning from one that was gold dominant with secondary zinc, to one that is zinc dominant with secondary gold is to be seen. The same could be said of Hole 078. Although, MAP-078 visually shows a thinner breccia package and might suggest the zone is pinching out

Hole 080 seems to be drilled in a part were no previous drilling had taken place before but with a little of hindsight following hole 077 and 078, thus hopefully intercepts the gold dominant zone.

I believe the last RNS did not do much to provide confidence in investors by failing to provide further information as to how many holes have been drilling since the investor's call and what is the status of the drill rigs. One would assume they are still drilling but that is not confirmed. We do not know how many holes will be reported in the next RNS either.

It looks like a bad time to buy. Looking at the graph, having lost the 50 day moving average at 220p (Bearish signal) and failing to keep the resistance at about 200p there are no more resistance levels in the way down until the 100 day moving average at 133p. Risky entry at this price in my view.

Looking ready to move higher. It has broken the 50 day moving average which is pretty bullish. If we manage to close above 3.26p, I think we could see a re-rate in the next couple of days.

Looking at the market cap of other "prospective" producers there is no doubt this is at a discount.

88E= £156.53 million
UKOG: £35.56
Serinus: £36.50 million

Agree. Solid RNS. Glad that even during this challenging time the company has been able start 2021 with over 8,000 ounces of gold produced, comfortably exceeding internal forecast.

With resistance broken at 0.48p we could see 0.70p. Once resistance is broken it is not the time to sell.

MJW418. Well clearly I took the time of going through the available information in order to decide whether I should invest. I though that was what we were supposed to do. The information I have posted may help another potential investors to make a decision.

3 July 2020:

Catenae asi the Cov-ID project was a joint initiative by a consortium of companies, led by the Z/Yen Group.

Although the proof-of-concept stage of the app was positive, the board said there was no guarantee that it would be commercialised, nor that in the event that it was commercialised, that material revenues would be generated by the company.

"The scope of the pilot trial was ambitiously expanded midway through to include the one-way validation usage on top of the initial two-way validation usage objective," noted interim chief executive officer Guy Meyer.

"Some minor graphic design refinements, based on NPH's feedback, will be completed within the next three weeks and then the Cov-ID app will be ready to be rolled out commercially across the UK and beyond to the benefit of businesses and organisations alike as the nations of the world begin to return to a semblance of normality."

22 February 2021:
"As a participant, we look forward to joining the discussions and highlighting the commercial benefits of the Digital Identity Policy, as well as advising how organisations should handle and protect people's data. Given that Catenae is ISO 27001 accredited and has blockchain at the core of its platform, the Company is well placed to leverage opportunities in this space".

29 January 2021
The pilot commenced on 28 January 2021 and will run for the next 12 weeks until the end of April 2021. Although the pilot is not expected to generate substantial revenues for the Company, it endorses the Company's Covid-19 testing proposition.

Zak Mir noted recently: "However, believers in a permanent state of pandemic, and an infinite number of variants, might regard Catenae as a winner in such a scenario. The rise in the share price suggests that they are awaiting imminent news regarding digital passport trials / contracts".

It seems to me that it is very unlikely that the government is looking for a provider as according to the above information they may have developed their own system? So far It looks like speculation rather than any substance for the share price increase.

John Meyer, Mining analyst and partner at SP Angel describes the results as "astonishing good results".

https://www.**********.co.uk/articles/john-meyer-on-rare-earths-and-3-resource-companies-plus-glen-goodman-on-bitcoin-f85c008